Hybio Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yu Pinxiang

Algemeen directeur

CN¥1.8m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	5.5yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	3.1yrs
Gemiddelde ambtstermijn bestuur	4.7yrs

Recente managementupdates

Recent updates

CEO

Yu Pinxiang (51 yo)

5.5yrs

Tenure

CN¥1,842,600

Compensatie

Ms. Pinxiang Yu serves as Director of Hybio Pharmaceutical Co., Ltd. since May 31, 2019 and serves as its Executive President. She served as a Vice President of Production Department at Hybio Pharmaceutica...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yu Pinxiang	Executive President & Director	no data	CN¥1.84m	0.060% CN¥ 6.3m
Honghong Tu	VP, CFO & Accounting Supervisor	3.3yrs	CN¥649.80k	geen gegevens
Di Yang	VP, Secretary & Director	2.8yrs	CN¥781.00k	geen gegevens
Zhaohui Zeng	Vice President	3.3yrs	CN¥1.19m	geen gegevens
Min Zhang	Vice President	2.9yrs	CN¥616.50k	geen gegevens
Heng Quan	Vice President of Human Resource & Administration Department	no data	CN¥840.50k	geen gegevens
Yu Liu	Vice President of Marketing	no data	CN¥398.30k	geen gegevens

3.1yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300199 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yu Pinxiang	Executive President & Director	5.5yrs	CN¥1.84m	0.060% CN¥ 6.3m
Di Yang	VP, Secretary & Director	4.6yrs	CN¥781.00k	geen gegevens
Lian Zhong	Independent Director	3.3yrs	CN¥60.00k	geen gegevens
Shaobin Zeng	Non-Independent Director	4.8yrs	CN¥65.70k	2.46% CN¥ 258.0m
Lu Yang	Member of Non-Employee Supervisory Board	2.9yrs	geen gegevens	geen gegevens
Qingyang Li	Chairman of Supervisory Board	5.5yrs	geen gegevens	geen gegevens
Yangming Tang	VP & Director	3.8yrs	CN¥976.90k	geen gegevens
Wenyan Hu	Independent Director	2.9yrs	CN¥120.00k	geen gegevens
Shaoqiang Zeng	Vice Chairman	15yrs	CN¥60.10k	8.15% CN¥ 855.2m
Shaogui Zeng	Chairman	15yrs	CN¥1.12m	12.41% CN¥ 1.3b
Lin Liang	Supervisor	no data	geen gegevens	geen gegevens

4.7yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300199 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Hybio Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.045 loss per share (vs CN¥0.15 loss in 3Q 2023)

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.068 loss in 2Q 2023)

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: CN¥0.02 loss per share (vs CN¥0.02 profit in 1Q 2023)

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: CN¥0.15 loss per share (vs CN¥0.05 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.049 loss in 2Q 2022)

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.06 loss in 1Q 2022)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.096 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.049 loss per share (vs CN¥0.058 loss in 2Q 2021)

Hybio Pharmaceutical Co., Ltd. (SZSE:300199) agreed to acquire 10.81% stake in Hybio Biotechnology (Dali) Co., Ltd. from Dazhong Transportation (Group) Co., Ltd. (SHSE:600611) for CNY 20 million.

First quarter 2022 earnings released: CN¥0.06 loss per share (vs CN¥0.026 profit in 1Q 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.025 in 1Q 2020)

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥5.60

New 90-day low: CN¥6.66

New 90-day low: CN¥7.17

New 90-day low: CN¥7.43

Third quarter earnings released

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 14, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd